A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Nonproliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)

Trial Profile

A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Nonproliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs BI 1467335 (Primary)
  • Indications Diabetic retinopathy
  • Focus Adverse reactions
  • Acronyms ROBIN Study
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 03 Apr 2018 Planned End Date changed from 21 Nov 2018 to 23 May 2019.
    • 03 Apr 2018 Planned primary completion date changed from 29 Aug 2018 to 28 Feb 2019.
    • 11 Jan 2018 According to a Pharmaxis media release, data are expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top